Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

Slides:

Advertisements

Similar presentations

Analgesic ACM 7/29/021 Time-Specific Measurements vs. Time-Weighted Average for Pain in Chronic and Acute Analgesia Trials Laura Lu, Ph.D Office of Biostatistics,

Advertisements

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Frequency of COP cells in control mice (caALK2) #1#2#3#4Average (%) Baseline (WT) undetectable Baseline (caALK2) 0.25 Day Day

March 10th, 2014 Efficacy Endpoints for Anticonvulsant Therapies Interview 1.

1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.

Journal of the American Medical Association (JAMA), 2004, 291:

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy and Safety of Tadalafil in Men With Erectile.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Omeprazole for the Treatment of Symptomatic.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.

Copyright © 2003 American Medical Association. All rights reserved.

Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase.

Mean Responses on PGI-Improvement Primary Endpoint at Week 12

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo David S. Baldwin, Satoshi Asakura, Tsukasa Koyama,

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.

Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation Satish S.C. Rao, Eamonn M.M. Quigley,

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

COMMIT/CCS-2 major efficacy results

Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation Satish S.C. Rao, Eamonn M.M. Quigley,

Global Projections for Diabetes:

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Managing Hereditary Angioedema

Volume 139, Issue 6, Pages e2 (December 2010)

Volume 10, Issue 7, Pages (July 2018)

Chronic Idiopathic Urticaria:

Charles D. Gerson, Mary-Joan Gerson

Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study Sigrun Chrubasik, MD, Elon Eisenberg, MD, Edith Balan,

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

N3-378 Template 12/31/2018 7:52 PM 8 8.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

FX006 Pivotal Ph 2b Data September , 2015

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee Najib.

Volume 130, Issue 2, Pages (February 2006)

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis Gary R. Lichtenstein,

Outcomes in SCS Trials Ali Rezai MD.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Obsessive-Compulsive Disorder: Pharmacotherapy

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Acute pain: combination treatments and how we measure their efficacy

Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study G.

Volume 153, Issue 5, Pages e2 (November 2017)

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pramlintide Therapy Part 1of 2

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

Injected Morphine in Postoperative Pain

PHOENIX I: PASI 75 Response After 12 Weeks

Presentation transcript:

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment PED Pain Responders Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day *** *** *** *** % of Patients n=545 n=491 n=318 n=232 n=234 n=159 *** P≤0.001 vs placebo PED= Patient Experience Diary

Proportion of Patients Achieving a PGIC Score of “Very Much Improved” or “Much Improved” at Week 12 of Stable Dose Treatment PGIC Responders Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day *** *** *** *** % of Patients n=566 n=507 n=344 n=239 n=251 n=175 *** P<0.001 vs placebo PGIC= Patient Global Impression of Change

2-Measure Composite Responders Percentage of 2-Measure Composite Responders at Week 12 of Stable Dose Treatment 2-Measure Composite Responders Placebo Milnacipran 100 mg/day Milnacipran 200 mg/day *** *** *** ** % of Patients n=542 n=490 n=316 n=230 n=239 n=159 **P<0.01; *** P<0.001 vs placebo